Omeros Corp (@OmerosCorp) header
Omeros Corp (@OmerosCorp) profile picture

Life Science

Seattle WA
Joined February 2013
Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)Photo by Omeros Corp (@OmerosCorp)
Omeros is honored to receive @RareDiseases’ 2026 Industry Innovation Award for YARTEMLEA. This recognition reflects years of dedication by the Omeros team. Their work has brought a much-needed therapy to patients facing a serious, often fatal condition. We thank NORD for this honor and for its vital work on behalf of people living with rare diseases and their families — advancing research and care, advocating for patients, and ensuring their voices are heard. NORD’s announcement: rarediseases.org/nord-announ… Learn more about YARTEMLEA at YARTEMLEA.com. #RareDisease, #Yartemlea, #Omeros
2
2
2
12
883
A major access milestone for patients with TA-TMA: CMS has granted NTAP status for #YARTEMLEA, the first and only FDA-approved therapy for adults and children with TA-TMA. Beginning Oct. 1, eligible hospitals will receive additional Medicare reimbursement.
1
2
1
10
607
Access to YARTEMLEA® has now been simplified. Effective July 1, YARTEMLEA® is assigned HCPCS J-code J1289, establishing reimbursement identification, enhancing coding clarity, and helping facilitate access for patients and providers. #TATMA
2
2
1
8
1,058
We are pleased to announce FDA approval of YARTEMLEA® (narsoplimab-wuug). First and only approved lectin pathway inhibitor. First and only therapy indicated for TA-TMA. Learn more here: bit.ly/497VHeF #YARTEMLEA #narsoplimab #ComplementInhibition #RareDisease #TMAtreatment #NowApproved #MASP2inhibitor #tma #hsct #omeros #FDA
4
21
903
#NovoNordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor #zaltenibart with best-in-class potential across multiple therapeutic areas of complement-driven disorders. Deal valued up to $2.1B plus tiered royalties. Learn more: bit.ly/47r7wg8 bit.ly/4nKvdG6 #Raredisease #PNH #C3G #IgAN #aHUS #complementinhibition
1
1
10
1,078
Omeros announces robust improvement in survival for #narsoplimab expanded access program in #TA-TMA over external control. More info: shorturl.at/NA9fy #complementinhibitor #omeros
2
8
858
Omeros Corporation announced two presentations that will be featured at the 2025 Tandem Meetings – February 12-15, 2025 in Honolulu, HI. Both presentations report real world outcomes from patients with TA-TMA treated with narsoplimab supplied by Omeros under an expanded access program. shorturl.at/D2nrP #TA-TMA #complementinhibitor #Tandem25
7
730
Omeros announces newly completed sensitivity analyses demonstrating robustness of previously announced survival superiority over external control in #TA-#TMA More info: shorturl.at/Ft34g #narsoplimab #complementinhibitor #omeros
9
564
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with #TA-#TMA. Narsoplimab BLA will be resubmitted to FDA as soon as possible. #ComplementInhibition
1
1
12
857
Attending #ASH24? Come visit #OMEROS at booth 321 to learn about #zaltenibart, our lead investigational MASP-3 inhibitor for #PNH.
8
403
#OMEROS announces upcoming presentations at #ASH24, highlighting progress in late-stage development of lead MASP-3 inhibitor #zaltenibart in #PNH. More info: investor.omeros.com/news-rel…
6
496
Omeros provides update on progress toward BLA resubmission. More info: investor.omeros.com/news-rel… #TA-#TMA #transplant #complementinhibitor
1
3
318
Omeros' zaltenibart (OMS906), the first-in-class MASP-3 inhibitor, has received FDA rare pediatric disease designation for #C3G, a devastating kidney disorder affecting children and young adults with no approved treatments. C3G can lead to end-stage renal disease within a decade. Zaltenibart is expected to have important advantages over other alternative pathway inhibitors. Omeros is planning for Phase 3 clinical trials with zaltenibart in both C3G and PNH. shorturl.at/kiF3V #NephCure #ISGD #PNH
6
354
In support of #PNHAwarenessWeek, OMEROS is continuing to listen to patients about their journeys. We’re proud of the progress we’re making to target and treat the ongoing unmet needs of patients living with PNH.
1
4
259
OMEROS, in recognition of #PNHAwarenessWeek, wants to highlight the importance of supporting the PNH community with resources and education. Learn more: aamds.org/what-you-can-do-pn…
2
205
Join Omeros at #Tandem24 on February 22, from 6:45 PM-7:45 PM, for a presentation of Poster 186: Real-World Experience with Narsoplimab (OMS721) for the Treatment of Transplant-Associated Thrombotic Microangiopathy #TA-#TMA shorturl.at/hvwJ6
4
346
#Omeros announces that 2 abstracts (573 & 4082) directed to #OMS906—an investigational MASP-3 inhibitor—will be presented at #ASH December 10-11, 2023 in San Diego. Both are now available on the ASH website at hematology.org More information here: tinyurl.com/2y2e9k8r
2
7
613